Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

26.55 +0.00 (+0.02%)
Streaming Delayed Price Updated: 10:44 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
 
Via Benzinga
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
 
Via Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
 
Via Benzinga
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Analyst Expectations For Celldex Therapeutics's Future
 
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
Analyst Expectations For Celldex Therapeutics's Future
 
Via Benzinga
Unveiling 4 Analyst Insights On Celldex Therapeutics
 
Via Benzinga
Celldex Therapeutics: Q4 Earnings Insights
 
Via Benzinga
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
 
Via Benzinga
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks. 
Via Investor's Business Daily
Top Picks 2024: Celldex Therapeutics, Inc.
Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to... 
Via Talk Markets
Top 4 Health Care Stocks That May Crash This Month
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare. 
Via InvestorPlace
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
 
Via Benzinga
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share. 
Via Benzinga
4 Analysts Have This to Say About Celldex Therapeutics
 
Via Benzinga
Why Celldex Therapeutics Blasted 13% Higher on Monday
The biotech's CSU treatment advanced in the laboratory. 
Via The Motley Fool
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.